Abstract
Early detection of cognitive decline may lead to more effective treatment. Clinical cognitive assessment is essential for early detection, but must be brief with easily interpretable results. The present study defines and evaluates a 30- minute cognitive battery consisting of a subset of tests that comprise a longer computerized battery recently validated in detecting mild cognitive impairment (MCI). Participants were from three tertiary care memory clinics and an assisted living facility (final group: N=161) with consensus diagnoses of cognitively healthy, MCI, or mild dementia. A comprehensive NeuroTrax battery evaluated memory, executive function, visual spatial perception, verbal function, information processing speed, and motor skills. Validity of a single summary measure (MCI Score) designed for dementia detection and built exclusively from tests of memory, executive function, and visual spatial perception was evaluated with receiver operating characteristic (ROC) analysis. Discriminant validity (area under the curve: AUC) was at least as large for the 6- parameter MCI Score as for a 20-parameter score necessitating administration of the entire battery. Further, the MCI Score had a larger AUC with reduced variance relative to its constituent parameters. AUC for distinguishing dementia was 0.886; AUC for distinguishing cognitively healthy was 0.823. Finally, the MCI Score discriminated among all three diagnostic groups (ANOVA; F[2,150]=52.54, p < 0.001). Hence a reduced NeuroTrax battery (30 minutes) with MCI Score is a useful clinical tool for summarizing cognitive data relevant to early dementia detection.
Keywords: dementia, mci, early detection, cognitive assessment
Current Alzheimer Research
Title: Towards Practical Cognitive Assessment for Detection of Early Dementia: A 30-Minute Computerized Battery Discriminates as Well as Longer Testing
Volume: 2 Issue: 2
Author(s): Glen M. Doniger, David M. Zucker, Avraham Schweiger, Tzvi Dwolatzky, Howard Chertkow, Howard Crystal and Ely S. Simon
Affiliation:
Keywords: dementia, mci, early detection, cognitive assessment
Abstract: Early detection of cognitive decline may lead to more effective treatment. Clinical cognitive assessment is essential for early detection, but must be brief with easily interpretable results. The present study defines and evaluates a 30- minute cognitive battery consisting of a subset of tests that comprise a longer computerized battery recently validated in detecting mild cognitive impairment (MCI). Participants were from three tertiary care memory clinics and an assisted living facility (final group: N=161) with consensus diagnoses of cognitively healthy, MCI, or mild dementia. A comprehensive NeuroTrax battery evaluated memory, executive function, visual spatial perception, verbal function, information processing speed, and motor skills. Validity of a single summary measure (MCI Score) designed for dementia detection and built exclusively from tests of memory, executive function, and visual spatial perception was evaluated with receiver operating characteristic (ROC) analysis. Discriminant validity (area under the curve: AUC) was at least as large for the 6- parameter MCI Score as for a 20-parameter score necessitating administration of the entire battery. Further, the MCI Score had a larger AUC with reduced variance relative to its constituent parameters. AUC for distinguishing dementia was 0.886; AUC for distinguishing cognitively healthy was 0.823. Finally, the MCI Score discriminated among all three diagnostic groups (ANOVA; F[2,150]=52.54, p < 0.001). Hence a reduced NeuroTrax battery (30 minutes) with MCI Score is a useful clinical tool for summarizing cognitive data relevant to early dementia detection.
Export Options
About this article
Cite this article as:
Doniger M. Glen, Zucker M. David, Schweiger Avraham, Dwolatzky Tzvi, Chertkow Howard, Crystal Howard and Simon S. Ely, Towards Practical Cognitive Assessment for Detection of Early Dementia: A 30-Minute Computerized Battery Discriminates as Well as Longer Testing, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585792
DOI https://dx.doi.org/10.2174/1567205053585792 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidant Agents in Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease
Current Pharmaceutical Design Drug-Delivery Systems of Green Tea Catechins for Improved Stability and Bioavailability
Current Medicinal Chemistry Medicinal Chemistry of the Epigenetic Diet and Caloric Restriction
Current Medicinal Chemistry Optimizing Modifiable and Lifestyle-related Factors in the Prevention of Dementia Disorders with Special Reference to Alzheimer, Parkinson and Autism Diseases
Current Nutrition & Food Science Dietary Lipids and Alzheimer’s Disease
Current Alzheimer Research Anti-Amyloid Treatments in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Neuronal Cell Death in Alzheimers Disease and a Neuroprotective Factor, Humanin
Current Neuropharmacology Rational Basis for the Use of Bergamot Essential Oil in Complementary Medicine to Treat Chronic Pain
Mini-Reviews in Medicinal Chemistry Direct and Indirect Measurement of Temporal Horn Volume and Temporal Horn Index and its Neuropsychological Correlation in Mild Cognitive Impaired and Alzheimer Diseased Patients
Current Medical Imaging Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond
Current Medicinal Chemistry Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Gender and Cardiovascular Mortality in Northern and Southern European Populations
Current Pharmaceutical Design Vicious Cycles Within the Neuropathophysiologic Mechanisms of Alzheimers Disease
Current Alzheimer Research Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and Targeting
Current Pharmaceutical Design High Serum Alkaline Phosphatase Levels in Relation to Multi-Cerebral Microbleeds in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia
Current Psychiatry Reviews